Keywords
Exploration
Accueil
Racine
Exploration
Accueil

Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « Keywords » - entrée « United States Food and Drug Administration (MeSH) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
United States (epidemiology) < United States Food and Drug Administration (MeSH) < United States Food and Drug Administration (legislation & jurisprudence)  Facettes :

List of bibliographic references indexed by United States Food and Drug Administration (MeSH)

Number of relevant bibliographic references: 13.
Ident.Authors (with country if any)Title
000496 (2021) Eun Ji Kim [États-Unis] ; Kevin Coppa [États-Unis] ; Jamie S. Hirsch [États-Unis] ; Sara Abrahams [États-Unis] ; Jennifer Johnson [États-Unis] ; Martin Lesser [États-Unis] ; Karina W. Davidson [États-Unis] ; Joseph Conigliaro [États-Unis]Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York.
000587 (2021) Susan Gould [Royaume-Uni] ; Susan L. Norris [États-Unis]Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19.
000766 (2021) Vakaramoko Diaby [États-Unis] ; Reem D. Almutairi [États-Unis] ; Ziyan Chen [États-Unis] ; Richard K. Moussa ; Abdrahmane Berthe [Canada]A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
000F14 (2020) Jonathan D. Alpern [États-Unis] ; Elie Gertner [États-Unis]Off-Label Therapies for COVID-19-Are We All In This Together?
000F26 (2020) H Holden ThorpNot throwing away our shot.
000F34 (2020) Kenichiro Sato [Japon] ; Tatsuo Mano [Japon] ; Atsushi Iwata [Japon] ; Tatsushi Toda [Japon]Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
001025 (2020) Lisa D. Burry [Canada] ; Jeffrey F. Barletta [États-Unis] ; David Williamson [Canada] ; Salmaan Kanji [Canada] ; Ryan C. Maves [États-Unis] ; Jeffrey Dichter [États-Unis] ; Michael D. Christian [Royaume-Uni] ; James Geiling [États-Unis] ; Brian L. Erstad [États-Unis]It Takes a Village…: Contending With Drug Shortages During Disasters.
001180 (2020) Ronald Chow [Canada] ; Charles B. Simone [États-Unis] ; Michael Lock [Canada]Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.
001339 (2020) Kyle Thomson [États-Unis] ; Herschel Nachlis [États-Unis]Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
001401 (2020) Benjamin N. Rome [États-Unis] ; Jerry Avorn [États-Unis]Drug Evaluation during the Covid-19 Pandemic.
001420 (2020) Shuofeng Yuan ; Jasper F W. Chan [Hong Kong] ; Kenn K H. Chik ; Chris C Y. Chan ; Jessica O L. Tsang ; Ronghui Liang ; Jianli Cao ; Kaiming Tang ; Lin-Lei Chen ; Kun Wen [République populaire de Chine] ; Jian-Piao Cai ; Zi-Wei Ye ; Gang Lu [République populaire de Chine] ; Hin Chu ; Dong-Yan Jin ; Kwok-Yung Yuen [Hong Kong]Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
001665 (2020) Tianxiao Liu [États-Unis] ; Songyuan Luo [États-Unis] ; Peter Libby [États-Unis] ; Guo-Ping Shi [États-Unis]Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
001888 (2020) Su-Jin Park [Corée du Sud] ; Kwang-Min Yu [Corée du Sud] ; Young-Il Kim [Corée du Sud] ; Se-Mi Kim [Corée du Sud] ; Eun-Ha Kim [Corée du Sud] ; Seong-Gyu Kim [Corée du Sud] ; Eun Ji Kim [Corée du Sud] ; Mark Anthony B. Casel [Corée du Sud] ; Rare Rollon [Corée du Sud] ; Seung-Gyu Jang [Corée du Sud] ; Min-Hyeok Lee [Corée du Sud] ; Jae-Hyung Chang [Corée du Sud] ; Min-Suk Song [Corée du Sud] ; Hye Won Jeong [Corée du Sud] ; Younho Choi [États-Unis] ; Weiqiang Chen [États-Unis] ; Woo-Jin Shin [États-Unis] ; Jae U. Jung [États-Unis] ; Young Ki Choi [États-Unis, Corée du Sud]Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "United States Food and Drug Administration (MeSH)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "United States Food and Drug Administration (MeSH)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    United States Food and Drug Administration (MeSH)
}}
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021